Parvovirus B19

Area of Science:

• Infectious Diseases
• Hematology
• Immunology

Background:

• Primary parvovirus B19 infection is a rare but serious cause of chronic anemia in immunocompromised individuals.
• Many immunocompromised hosts have prior B19 antibodies, conferring protection, but primary infection can occur.
• The most frequent outcome in compromised hosts is pure red-cell aplasia, leading to persistent anemia.

Purpose of the Study:

• To highlight parvovirus B19 as a critical cause of anemia in immunocompromised hosts.
• To outline diagnostic criteria and therapeutic strategies for parvovirus B19 infection.
• To emphasize the importance of monitoring patients post-treatment.

Main Methods:

• Diagnosis relies on detecting parvovirus B19 DNA in serum without specific IgG antibodies.
• Bone marrow examination may reveal giant pronormoblasts or absent red-cell precursors.
• Assessment involves clinical presentation, serological testing, and DNA detection.

Main Results:

• Anemia in these patients persists until neutralizing antibodies are present or administered.
• Successful treatment may involve red-cell transfusions, immune system modulation, and intravenous immunoglobulin (IVIG).
• Recurrence or worsening anemia necessitates re-evaluation of treatment, potentially including maintenance IVIG.

Conclusions:

• Parvovirus B19 should be suspected in immunocompromised patients with unexplained anemia and reticulocytopenia.
• Effective management requires a multi-faceted approach including supportive care and immunomodulation.
• Awareness of B19 variants is important for accurate diagnosis with molecular methods.